C. Yurdaydin Et Al. , "Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)," 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver , vol.44, Vienna, Austria, 2006
Yurdaydin, C. Et Al. 2006. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026). 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver , (Vienna, Austria).
Yurdaydin, C., Sollano, J., Hadziyannis, S., Kaymakoglu, S., Sherman, M., Brett-Smith, H., ... Vaughan, J.(2006). Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026) . 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, Austria
Yurdaydin, C. Et Al. "Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)," 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, Austria, 2006
Yurdaydin, C. Et Al. "Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)." 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver , Vienna, Austria, 2006
Yurdaydin, C. Et Al. (2006) . "Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)." 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver , Vienna, Austria.
@conferencepaper{conferencepaper, author={C. Yurdaydin Et Al. }, title={Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)}, congress name={41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver}, city={Vienna}, country={Austria}, year={2006}}